US4327053090
© PR Newswire
22.01.2026
THAR
LISTED
NASDAQ
Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering
News Preview
NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the closing of its previously announced underwritten registered direct offering which included the issuance of 1,800,00...
Themefolio
Profiler
Peergroup
© PR Newswire
20.01.2026
THAR
LISTED
NASDAQ
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering
News Preview
NEW YORK, Jan. 20, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial markets, today announced the pricing of a $55 million registered offering.
Tharimmune, Inc. operates a differentiated digital asset treasury str...
Themefolio
Profiler
Peergroup
© PR Newswire
18.12.2025
THAR
LISTED
NASDAQ
Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network
News Preview
Milestone Underscores Accelerating Institutional Adoption of Blockchain Technology and Aligns with Tharimmune's Canton Coin Treasury StrategyNEW YORK, Dec. 18, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional financial mar...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© PR Newswire
13.11.2025
THAR
LISTED
NASDAQ
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids
News Preview
RED BANK, N.J., Nov. 13, 2025 /PRNewswire/ -- Tharimmune, Inc. (Nasdaq: THAR) ("Tharimmune" or the "Company"), a digital asset treasury company with a clinical-stage biotechnology function, today announced an update from the biotechnology side of the business. Its lead clinical asset, TH104 (nalmefene buccal film...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© PR Newswire
06.11.2025
THAR
LISTED
NASDAQ
Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy
News Preview
Led by DRW and Liberty City Ventures, Transaction Cements Tharimmune as First Public Company to Deliver Canton-Aligned DAT Strategy
Net Proceeds Support Acquisition of Canton Coin
and Active Network Participation via Validator Infrastructure an...
Themefolio
Profiler
Peergroup
© PR Newswire
03.11.2025
THAR
LISTED
NASDAQ
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy
News Preview
Other Participants Include ARK Invest, Bitwave, Broadridge, Clear Street, Copper, Digital Asset, Feynman Point Asset Management, Five North, Kaiko, Kenetic, Kraken, LendOS, Lukka, Nima Capital, MPCH, Obsidian Software, Polychain Capital, Proof Group, SBI Group, The Tie, Tradeweb Markets, and 7RIDGE...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
20.08.2025
THAR
LISTED
NASDAQ
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
News Preview
RED BANK, NJ / ACCESS Newswire / August 20, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and unmet medical needs announced positive results from a recent pharmacokinetic (PK) si...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.08.2025
THAR
LISTED
NASDAQ
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl
News Preview
RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
05.08.2025
THAR
LISTED
NASDAQ
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
News Preview
RED BANK, NJ / ACCESS Newswire / August 5, 2025 / Tharimmune, Inc. (NASDAQ:THAR), ("Tharimmune" or the "Company), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today proudly announced the appointment of Nancy Davis, a gl...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
23.07.2025
THAR
LISTED
NASDAQ
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
News Preview
RED BANK, NJ / ACCESS Newswire / July 23, 2025 / Tharimmune, Inc. (the "Company" and "Tharimmune") (Nasdaq Capital Market:THAR), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced the pricing of a registered direct public offering (the "RD Offering")...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
17.06.2025
THAR
LISTED
NASDAQ
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
News Preview
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / June 17, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, today announced significant appointments to its executive leadership and board of directors, reinforcing its commitment to advancing its...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
19.05.2025
THAR
LISTED
NASDAQ
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
News Preview
BRIDGEWATER, NJ / ACCESS Newswire / May 19, 2025 / Tharimmune, Inc. (Nasdaq:THAR), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics, today announced the appointment of James Gordon Liddy (CDR US Navy SEAL (Ret)) as a strategic advisor. Mr. Liddy, an internationally recognized expert on counterterrorism and cr...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESSWIRE
06.05.2025
THAR
LISTED
NASDAQ
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
News Preview
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / May 6, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology released pharmacokinetic and metabolism data from its Phase 1 study of TH104, a buccal...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
01.05.2025
THAR
LISTED
NASDAQ
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
News Preview
BRIDGEWATER, NJ / ACCESS Newswire / May 1, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology announced abstracts featuring clinical data on its lead drug candidate, TH104, have been accep...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.04.2025
THAR
LISTED
NASDAQ
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
News Preview
BRIDGEWATER, NJ / ACCESS Newswire / April 30, 2025 / Tharimmune, Inc., (NASDAQ:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, today announced the appointment of Clay Kahler and Gary Stetz to its Board of Directors, i...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
28.04.2025
THAR
LISTED
NASDAQ
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
News Preview
BRIDGEWATER, NEW JERSEY / ACCESS Newswire / April 28, 2025 / Tharimmune, Inc., (Nasdaq:THAR) ("Tharimmune" or the "Company") a clinical-stage biopharmaceutical company focused on developing innovative therapeutics in inflammation & immunology, recently announced positive feedback from the U.S. Food and Drug Administration (F...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
15.04.2025
THAR
LISTED
NASDAQ
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
News Preview
BRIDGEWATER, NJ / ACCESS Newswire / April 15, 2025 / Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company advancing novel solutions in immunology and oncology, today announced the appointment of Vincent LoPriore, Founder of Gravitas Capital and Co-Founder of President Street Global, to its Board of Directors, increasing the size o...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
07.04.2025
THAR
LISTED
NASDAQ
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
News Preview
BRIDGEWATER, NJ / ACCESS Newswire / April 7, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced preclinical data from its expanded pipeline with HS1940, a dual-target multispecific biologic engineered to bind to bot...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
31.03.2025
THAR
LISTED
NASDAQ
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
News Preview
-Received positive feedback on New Drug Application submission via the 505(b)(2) pathway-Company leveraging existing human pharmacokinetic data with TH104-Advancing CMC plan to meet requirements of a New Drug Application BRIDGEWATER, NJ / ACCESS Newswire / March 31, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company&...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
24.03.2025
THAR
LISTED
NASDAQ
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
News Preview
BRIDGEWATER, NJ / ACCESS Newswire / March 24, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its novel oral antibody, TH023. In a murine model, a proprietary protease enzyme stab...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.03.2025
THAR
LISTED
NASDAQ
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
News Preview
BRIDGEWATER, NJ / ACCESS Newswire / March 4, 2025 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company focused on immunology and inflammation, today announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both Prog...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
27.01.2025
THAR
LISTED
NASDAQ
Tharimmune to Present at the Microcap Conference 2025
News Preview
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlan...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
16.12.2024
THAR
LISTED
NASDAQ
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
News Preview
BRIDGEWATER, NJ / ACCESSWIRE / December 16, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced plans for initiating a Phase 2 study evaluating TH104 in patients suffering from moderate-to-s...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
06.12.2024
THAR
LISTED
NASDAQ
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
News Preview
BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approxim...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
18.11.2024
THAR
LISTED
NASDAQ
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
News Preview
Significant correlation shown between blood levels and symptom relief; TH104 was well tolerated with no unexpected treatment-emergent adverse eventsPhase 2 preliminary data for chronic pruritus in primary biliary cholangitis expected in 2025BRIDGEWATER, NJ / ACCESSWIRE / November 18, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
13.11.2024
THAR
LISTED
NASDAQ
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
News Preview
BRIDGEWATER, NJ / ACCESSWIRE / November 13, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today that the European Patent Office intends to grant the Company a patent covering...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
04.11.2024
THAR
LISTED
NASDAQ
Tharimmune Announces Upcoming Conference Presentations
News Preview
BRIDGEWATER, NJ / ACCESSWIRE / November 4, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.Randy Milby, Chief E...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
30.10.2024
THAR
LISTED
NASDAQ
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
News Preview
BRIDGEWATER, NJ / ACCESSWIRE / October 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, received positive feedback from a Scientific Advice meeting with the European Medicines Agency (...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
28.10.2024
THAR
LISTED
NASDAQ
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
News Preview
TH104, the Company's lead candidate for moderate-to-severe pruritus in chronic liver disease, showed no opioid withdrawal effects, reinforcing safety profileTH104 was well tolerated with no unexpected treatment-emergent adverse events, supporting further clinical developmentCompany expects Phase 2 topline data for chronic pruritus in primary biliar...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.10.2024
THAR
LISTED
NASDAQ
Tharimmune Announces Upcoming Conference Presentations
News Preview
BRIDGEWATER, NJ / ACCESSWIRE / October 25, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces that management will be participating in two upcoming conferences.Nir Barak, M.D., Chi...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
